EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Genome Sequencing Uncovers Additional Findings in Phelan‐ McDermid Syndrome

Rachel Gore Moses iD, Morgan Similuk, Alexandra Hehn, Rylee Duncan, Margaret Pekar, Eliza Gordon-Lipkin, Maria T Acosta, Deena Zeltser, Nadjalisse Reynolds-Lallement, Latha Soorya, Mustafa Sahin, Tess Levy und 10 weitere

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · 2025

DOI: 10.1002/ajmg.b.33036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2025. Verfasst von Rachel Gore Moses und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centralized Sequencing Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Chromosome Disorders, Nerve Tissue Proteins. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NINDS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phelan‐McDermid syndrome (PMS) is a genetic condition caused by deletions of chromosome 22q13.3 or pathogenic variants in the SHANK3 gene. Neurologic features typically include intellectual disability, autism spectrum disorder, hypotonia, and absent speech, though there is considerable variability even among individuals with the same molecular cause. This prospective study aimed to explore the utility of genome sequencing to identify additional molecular diagnoses that may contribute to variability in a cohort of patients with PMS. Twenty probands diagnosed with PMS (60% with a 22q13 deletion, 40% with a SHANK3 variant) underwent trio or duo genome sequencing and chromosomal microarray. This analysis identified a second molecular finding associated with a neurological condition in 3/20 participants. Molecular diagnoses related to neurological phenotypes included: (1) spinal muscular atrophy, lower extremity‐predominant, 2A, autosomal dominant (SMALED2A), (2) spastic paraplegia 7, and (3) 16p11.2 deletion syndrome. Five additional new molecular diagnoses were associated with a clinically actionable secondary or incidental finding. This exploratory study provides early evidence for the potential utility of expanded sequencing among individuals with PMS, even for those without phenotypic features outside of the expected range.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chromosome DisordersNerve Tissue ProteinsHumansChromosomes, Human, Pair 22MaleFemaleChromosome DeletionChildChild, PreschoolWhole Genome SequencingAdolescentPhenotypeProspective StudiesAdultIntellectual DisabilityYoung Adult

Stichwörter der Autor:innen

Phelan‐McDermid syndromedual diagnosisgenome sequencingneurodevelopment

Substanzen

Nerve Tissue ProteinsSHANK3 protein, human

Autor:innen und Institutionen

  • Centralized Sequencing Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Neurodevelopmental and Behavioral Phenotyping Service, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Psychology, Ohio State University, Columbus, Ohio, USA.
  • Metabolic Medicine Branch, National Genome Research Institute, NIH, Bethesda, Maryland, USA.
  • Undiagnosed Disease Program, National Genome Research Institute, NIH, Bethesda, Maryland, USA.
  • National Institute of Child Health and Human Development, NIH, Bethesda, Maryland, USA.

ORCID-Profile: Rachel Gore Moses

Förderung

  • NCATS NIH HHS
  • NINDS NIH HHS
  • Intramural NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases
  • National Center for Advancing Translational Sciences (NCATS)
  • NIMH NIH HHS
  • Data Management and Coordinating Center: Rare Diseases Clinical Research Network
  • National Institute of Mental Health

Zitieren

APA

Moses, R. G., Similuk, M., Hehn, A., Duncan, R., Pekar, M., Gordon-Lipkin, E., Acosta, M. T., Zeltser, D., Reynolds-Lallement, N., Soorya, L., Sahin, M., Levy, T., Kolevzon, A., Buxbaum, J. D., Berry-Kravis, E., Powell, C. M., Bernstein, J. A., Tokita, M., Seifert, B. A., …, & Thurm, A. (2025). Genome Sequencing Uncovers Additional Findings in Phelan‐ McDermid Syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. https://doi.org/10.1002/ajmg.b.33036

Vancouver

Moses RG, Similuk M, Hehn A, Duncan R, Pekar M, Gordon-Lipkin E, et al. Genome Sequencing Uncovers Additional Findings in Phelan‐ McDermid Syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2025. doi:10.1002/ajmg.b.33036

BibTeX
@article{Moses2025,
  author = {Moses, Rachel Gore and Similuk, Morgan and Hehn, Alexandra and Duncan, Rylee and Pekar, Margaret and Gordon-Lipkin, Eliza and Acosta, Maria T and Zeltser, Deena and Reynolds-Lallement, Nadjalisse and Soorya, Latha and Sahin, Mustafa and Levy, Tess and Kolevzon, Alexander and Buxbaum, Joseph D and Berry-Kravis, Elizabeth and Powell, Craig M and Bernstein, Jonathan A and Tokita, Mari and Seifert, Bryce A and Ghosh, Rajarshi and Walkiewicz, Magdalena A and Thurm, Audrey},
  title = {Genome Sequencing Uncovers Additional Findings in Phelan‐ McDermid Syndrome},
  journal = {American Journal of Medical Genetics Part B: Neuropsychiatric Genetics},
  year = {2025},
  doi = {10.1002/ajmg.b.33036}
}
Kostenlos starten →